Tvardi Therapeutics, Inc. (TVRD)
Last updated: 2026-10-24 14:41:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Tvardi Therapeutics, Inc. (TVRD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.94, with a market capitalization of $12.97M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.92 to $5.69. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$12.97M | |
$1.07 | |
$43.65 | |
$0.92 | |
$0.97 | |
107.28K | |
209.26K | |
-- | |
$5.69 | |
$0.92 | |
-- | |
-- |
Tvardi Therapeutics, Inc. (TVRD) Latest Closing Stock Price
Tvardi Therapeutics, Inc. (TVRD) last closed at $0.97 as of 2026-10-23 23:57:00, unchanged from the previous close of $0.97.
During the latest regular trading session, TVRD traded between $0.92 and $43.65, with a volume of 107.28K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Tvardi Therapeutics, Inc. (TVRD) 7-Day Stock Price Change
Over the past seven days, Tvardi Therapeutics, Inc. (TVRD) moved from $1.07 to $0.94, representing a decline of 12.62% ($0.14).
The stock traded between $0.92 and $1.09 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 126.33 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
TVRD 52-Week Price Position
Position in Range: 0.3%
TVRD is currently trading at $0.94, placing it 0.3% of the way from its 52-week low of $0.92 to its 52-week high of $5.69. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Tvardi Therapeutics, Inc. (TVRD)?
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Tvardi Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Tvardi Therapeutics, Inc. (TVRD) Stock on MEXC
Eligible investors can buy real shares of Tvardi Therapeutics, Inc. (TVRD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Tvardi Therapeutics, Inc. (TVRD) stock price today?
2.Is TVRD stock going up or down today?
3.What is TVRD pre-market price?
4.What is TVRD after-hours price?
5.Is TVRD stock trading now?
6.Where does TVRD sit relative to its 52-week high and low?
7.What sector is Tvardi Therapeutics, Inc. in?
8.What is Tvardi Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is TVRD valued in terms of P/E ratio and EPS?
10.Does Tvardi Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
TVRD Stock Calculator
Estimate the value between TVRD shares and USD.
TVRD Shares to USD
1.00 TVRD shares = 0.935 USD
Calculations are estimates based on the latest available price and are for reference only.


